A Phase I/IIa Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of SPN-812 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Phase of Trial: Phase I/II
Latest Information Update: 10 May 2017
At a glance
- Drugs Viloxazine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Therapeutic Use
- Sponsors Supernus Pharmaceuticals
- 18 Jun 2012 Additional lead trial investigator (Lowen M) identified as reported by ClinicalTrials.gov.
- 11 Nov 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 11 Nov 2010 Actual end date (Oct 2010) added as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History